DK3520805T3 - Sammensætninger til behandling af myelofibrose - Google Patents
Sammensætninger til behandling af myelofibrose Download PDFInfo
- Publication number
- DK3520805T3 DK3520805T3 DK19161424.7T DK19161424T DK3520805T3 DK 3520805 T3 DK3520805 T3 DK 3520805T3 DK 19161424 T DK19161424 T DK 19161424T DK 3520805 T3 DK3520805 T3 DK 3520805T3
- Authority
- DK
- Denmark
- Prior art keywords
- myelofibrose
- compositions
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 206010028537 myelofibrosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547932P | 2011-10-17 | 2011-10-17 | |
| EP12842601.2A EP2797620B1 (en) | 2011-10-17 | 2012-10-17 | Compositions for treating iron overload in thalassemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3520805T3 true DK3520805T3 (da) | 2021-04-19 |
Family
ID=48141315
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19161424.7T DK3520805T3 (da) | 2011-10-17 | 2012-10-17 | Sammensætninger til behandling af myelofibrose |
| DK21153891.3T DK3875104T3 (da) | 2011-10-17 | 2012-10-17 | Sammensætninger til behandling af ineffektiv erytropoiese |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21153891.3T DK3875104T3 (da) | 2011-10-17 | 2012-10-17 | Sammensætninger til behandling af ineffektiv erytropoiese |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20130243743A1 (enExample) |
| EP (3) | EP3520805B1 (enExample) |
| JP (4) | JP6092883B2 (enExample) |
| KR (4) | KR102079482B1 (enExample) |
| CN (3) | CN107837390A (enExample) |
| AU (4) | AU2012326207B2 (enExample) |
| BR (3) | BR122019023166B1 (enExample) |
| CA (1) | CA2852683A1 (enExample) |
| DK (2) | DK3520805T3 (enExample) |
| EA (2) | EA202090053A3 (enExample) |
| ES (3) | ES2869168T3 (enExample) |
| HK (2) | HK1250341A1 (enExample) |
| WO (1) | WO2013059347A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2561048T3 (es) | 2004-07-23 | 2016-02-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| ME00380B (me) | 2005-11-23 | 2011-10-10 | Acceleron Pharma Inc | Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US9526759B2 (en) | 2007-02-01 | 2016-12-27 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| KR101672156B1 (ko) | 2007-02-09 | 2016-11-02 | 악셀레론 파마 인코포레이티드 | 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
| CN107412734A (zh) | 2007-09-18 | 2017-12-01 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| LT3750552T (lt) | 2008-08-14 | 2023-06-26 | Acceleron Pharma Inc. | Gdf gaudyklės |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| MX385318B (es) | 2009-06-08 | 2025-03-18 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
| JP2012529294A (ja) | 2009-06-12 | 2012-11-22 | アクセルロン ファーマ， インコーポレイテッド | 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質 |
| ES2613523T3 (es) * | 2009-09-09 | 2017-05-24 | Acceleron Pharma, Inc. | Antagonistas de ActRIIb y dosificación y usos de los mismos |
| EP2501400B1 (en) | 2009-11-17 | 2017-11-01 | Acceleron Pharma, Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| WO2012064771A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma, Inc. | Actriia binding agents and uses thereof |
| WO2013055476A1 (en) | 2011-09-09 | 2013-04-18 | Anthrogenesis Corporation | Treatment of amyotrophic lateral sclerosis using placental stem cells |
| RU2018145985A (ru) | 2012-11-02 | 2019-02-18 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| KR102520970B1 (ko) * | 2014-03-21 | 2023-04-12 | 악셀레론 파마 인코포레이티드 | 액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법 |
| MX388380B (es) * | 2014-04-18 | 2025-03-19 | Acceleron Pharma Inc | Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes. |
| TN2016000553A1 (en) | 2014-06-13 | 2018-04-04 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| DK3227675T3 (da) * | 2014-12-03 | 2023-05-30 | Celgene Corp | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom |
| DK3286206T3 (da) | 2015-04-22 | 2021-05-03 | Biogen Ma Inc | Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme |
| WO2016183280A1 (en) * | 2015-05-13 | 2016-11-17 | Celgene Corporation | Treatment of beta-thalassemia using actrii ligand traps |
| CN108350057A (zh) * | 2015-05-20 | 2018-07-31 | 细胞基因公司 | 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法 |
| EP3370754A4 (en) * | 2015-11-04 | 2019-10-23 | Acceleron Pharma Inc. | METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE |
| CA3005975A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| EA201990226A1 (ru) | 2016-07-27 | 2019-08-30 | Акселерон Фарма Инк. | Способы и композиции для лечения миелофиброза |
| JP7280182B2 (ja) | 2016-10-05 | 2023-05-23 | アクセルロン ファーマ インコーポレイテッド | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| WO2018089715A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| SMT202400437T1 (it) | 2017-06-14 | 2024-11-15 | Celgene Corp | Metodi per trattare mielofibrosi associata a neoplasia mieloproliferativa e anemia |
| KR20250059538A (ko) | 2017-11-09 | 2025-05-02 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| JP7510875B2 (ja) | 2018-01-12 | 2024-07-04 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物 |
| KR20250133994A (ko) | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| KR20230004515A (ko) | 2020-03-20 | 2023-01-06 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 ii 키메라 및 이의 사용 방법 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CA3177830A1 (en) | 2020-05-13 | 2021-11-18 | Maria BECONI | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1265208A (en) | 1915-09-07 | 1918-05-07 | Edward C Kahn | Liquid-fuel burner. |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
| US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| ATE352638T1 (de) | 1995-04-11 | 2007-02-15 | Gen Hospital Corp | REVERSE ßTWO-HYBRIDß-SYSTEME |
| US5807839A (en) * | 1997-04-15 | 1998-09-15 | Advanced Viral Research Corp. | Method for stimulating red blood cell production |
| EP1147413B1 (en) | 1999-01-21 | 2006-04-05 | Metamorphix, Inc. | Growth differentiation factor inhibitors and uses therefor |
| US7842691B2 (en) * | 2002-10-15 | 2010-11-30 | Celgene Corporation | Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide |
| ES2561048T3 (es) | 2004-07-23 | 2016-02-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| LT3750552T (lt) * | 2008-08-14 | 2023-06-26 | Acceleron Pharma Inc. | Gdf gaudyklės |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| CA2770822C (en) * | 2009-08-13 | 2020-03-24 | Acceleron Pharma Inc. | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
-
2012
- 2012-10-17 EP EP19161424.7A patent/EP3520805B1/en active Active
- 2012-10-17 CA CA2852683A patent/CA2852683A1/en active Pending
- 2012-10-17 EA EA202090053A patent/EA202090053A3/ru unknown
- 2012-10-17 KR KR1020197025484A patent/KR102079482B1/ko active Active
- 2012-10-17 EP EP21153891.3A patent/EP3875104B1/en active Active
- 2012-10-17 BR BR122019023166-4A patent/BR122019023166B1/pt active IP Right Grant
- 2012-10-17 BR BR122019023174-5A patent/BR122019023174B1/pt active IP Right Grant
- 2012-10-17 ES ES19161424T patent/ES2869168T3/es active Active
- 2012-10-17 BR BR112014009528-0A patent/BR112014009528B1/pt active IP Right Grant
- 2012-10-17 DK DK19161424.7T patent/DK3520805T3/da active
- 2012-10-17 AU AU2012326207A patent/AU2012326207B2/en active Active
- 2012-10-17 DK DK21153891.3T patent/DK3875104T3/da active
- 2012-10-17 WO PCT/US2012/060650 patent/WO2013059347A1/en not_active Ceased
- 2012-10-17 CN CN201711069431.3A patent/CN107837390A/zh active Pending
- 2012-10-17 EA EA201490809A patent/EA034563B1/ru not_active IP Right Cessation
- 2012-10-17 EP EP12842601.2A patent/EP2797620B1/en active Active
- 2012-10-17 CN CN201280061672.2A patent/CN103987403B/zh active Active
- 2012-10-17 ES ES12842601T patent/ES2741477T3/es active Active
- 2012-10-17 US US13/654,191 patent/US20130243743A1/en not_active Abandoned
- 2012-10-17 KR KR1020227017193A patent/KR20220075438A/ko not_active Ceased
- 2012-10-17 ES ES21153891T patent/ES3010483T3/es active Active
- 2012-10-17 CN CN201711069457.8A patent/CN107693776A/zh active Pending
- 2012-10-17 KR KR1020147013325A patent/KR20140084211A/ko not_active Ceased
- 2012-10-17 KR KR1020207004201A patent/KR20200019261A/ko not_active Ceased
- 2012-10-17 JP JP2014537186A patent/JP6092883B2/ja active Active
-
2017
- 2017-01-23 US US15/413,184 patent/US20170137791A1/en not_active Abandoned
- 2017-02-09 JP JP2017022176A patent/JP6383821B2/ja active Active
- 2017-03-08 AU AU2017201580A patent/AU2017201580B2/en active Active
- 2017-07-28 US US15/663,361 patent/US20170327800A1/en not_active Abandoned
-
2018
- 2018-07-30 HK HK18109792.1A patent/HK1250341A1/zh unknown
- 2018-08-06 JP JP2018147507A patent/JP6796626B2/ja active Active
- 2018-09-26 HK HK18112295.7A patent/HK1252940A1/zh unknown
- 2018-10-11 AU AU2018247262A patent/AU2018247262B2/en active Active
-
2020
- 2020-08-07 US US16/987,756 patent/US20210207107A1/en active Pending
- 2020-08-24 JP JP2020140889A patent/JP2020186277A/ja active Pending
- 2020-12-09 AU AU2020286229A patent/AU2020286229A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3520805T3 (da) | Sammensætninger til behandling af myelofibrose | |
| EP2736491A4 (en) | BEPOTASTIN COMPOSITION | |
| DK2635282T3 (da) | Sammensætninger til behandling af myelofibrose | |
| EP2675909A4 (en) | GLUCOSYLSTEVIA COMPOSITION | |
| EP2720561A4 (en) | Stevia-COMPOSITION | |
| EP2713762A4 (en) | Stevia-COMPOSITION | |
| LT2791160T (lt) | Modifikuotos mrnr sudėtys | |
| DK2872152T3 (da) | Acellulære pro-tolerogene sammensætninger til behandling/forebyggelse af transplantatafstødning | |
| LT2742151T (lt) | Polimerazės kompozicija | |
| BR112013022112A2 (pt) | composição | |
| BR112013022102A2 (pt) | composição | |
| DK2686017T3 (da) | Oftalmisk sammensætning | |
| BR112014004395A2 (pt) | composição | |
| DK2739293T3 (da) | Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus | |
| DK2701733T3 (da) | Forbindelser til behandling af neuropsykiatriske forstyrrelser | |
| CO6930368A2 (es) | Composiciones de yodo-povidona estable | |
| SI3513806T1 (sl) | Sestava imunogena | |
| DK2836460T3 (da) | Fremgangsmåde til fremstilling af graphen | |
| DK2822568T3 (da) | Anvendelser af caseinsammensætninger | |
| DK2734212T3 (da) | Sammensætninger omfattende diclofenac til behandling af postoperativ smerte | |
| BR112013033808A2 (pt) | composição | |
| EP2730619A4 (en) | COMPOSITION | |
| DK3444238T3 (da) | Fremgangsmåde til fremstilling af difluormethylenforbindelser | |
| IL231907B (en) | Compounds and compositions for treatment of transthyretin-associated amyloidosis | |
| PT2739276T (pt) | Composição antisséptica |